Paul Ashton, President and Chief Executive Officer, pSivida Corp.

Dr. Ashton has over 25 years experience in drug delivery. He has invented and developed (with colleagues) Vitrasert (the first intravitreal drug delivery system to be approved by the FDA), Retisert (first FDA approved product for uveitis) and Iluvien (first sustained release product for DME approved in EU).

Dr. Ashton has served as President and Chief Executive Officer of pSivida Corp. since January 2009, where he was previously the Managing Director from January 2007 and Executive Director of Strategy from December 2005 to January 2007. From 1996 to 2005, Dr. Ashton was the President and Chief Executive Officer of Control Delivery Systems, Inc., a drug delivery company that he co-founded in 1991.

Dr. Ashton has authored over 200 peer reviewed publications, including original articles, chapters, books and abstracts. He also has over 70 issued patents. Before going into industry Dr. Ashton was on the faculty at the New England Eye Institute and prior to that on the faculty in both the Departments of Ophthalmology and Surgery at the University of Kentucky. Earlier in his career he worked as a pharmaceutical scientist at Hoffman-LaRoche. Dr. Ashton received a Bachelor of Science degree in chemistry from Durham University, England, and a Ph.D. in pharmaceutical science from the University of Wales.